DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Description
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged. Distinctive Features: The FY26 CTRA offers two funding levels: • Funding Level 1 to support smaller, less complex preclinical and/or clinical research. • Funding Level 2 to support larger, more complex preclinical and/or clinical research. The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories: • Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission. • Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field. Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed.
Eligibility
See official grant page for eligibility requirements
Industry Tags
About This Grant
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged. Distinctive Features: The FY26 CTRA offers two funding levels: • Funding Level 1 to support smaller, less complex preclinical and/or clinical research. • Funding Level 2 to support larger, more complex preclinical and/or clinical research. The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories: • Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission. • Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field. Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed.
Funding Information
- Estimated Total Program Funding
- $8,460,000
- Expected Number of Awards
- 6
Eligibility Overview
This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements.
Federal grant opportunities like this one are typically open to a range of applicant types. Common eligible organizations include:
- Nonprofits and 501(c)(3) organizations
- Small businesses and startups (especially for SBIR/STTR programs)
- State, local, and tribal governments
- Colleges, universities, and research institutions
- Individuals (for select programs in education, arts, and research)
Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.
How to Apply
- 1
Review the full opportunity
Read the complete Notice of Funding Opportunity (NOFO) for this Defense Health Agency Contracting Activity - DHACA program on its official page (https://www.grants.gov/search-results-detail/362851).
- 2
Confirm eligibility
Check that your organization meets every requirement set by Defense Health Agency Contracting Activity - DHACA — applicant type, location, registration status, and any prior-award restrictions.
- 3
Prepare required documents
Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.
- 4
Submit before the deadline
This opportunity closes on September 18, 2026. Submit at least 48 hours early — portal systems are often slow near closing time.
Grant Writing Tips
Proposals for healthcare programs such as those from Defense Health Agency Contracting Activity - DHACA are competitive — these tips can strengthen your application:
- ✓Start your application at least 4 weeks before the deadline — rushed proposals score lower.
- ✓Tailor your needs statement to match the funder's stated priorities, using their exact language where possible.
- ✓Have a colleague outside your team review your budget narrative before submitting — fresh eyes catch errors reviewers penalize.
More Grants from Defense Health Agency Contracting Activity - DHACA
Frequently Asked Questions
Who is eligible for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award?
This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements. Always confirm the full eligibility criteria on the official listing before applying.
How much funding does DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award provide?
The total estimated program funding for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award is $8,460,000.
When is the deadline for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award?
The application deadline for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award is September 18, 2026. Submit at least 48 hours early to avoid last-minute portal issues.
How do I apply for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award?
Apply for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award through the official grant page (https://www.grants.gov/search-results-detail/362851). Confirm your eligibility and prepare your application materials before the deadline.
Helpful Resources
Need help writing your grant application?
Try Instrumentl — Grant Writing Software →Starting a nonprofit to apply for grants?
Launch your nonprofit with Swyft Filings →GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.